Form SC14D9C - Written communication relating to third party tender offer
December 12 2023 - 3:56PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities Exchange Act of 1934
ICOSAVAX, INC.
(Name of
Subject Company)
ICOSAVAX, INC.
(Name of
Person Filing Statement)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
45114M109
(CUSIP Number
of Class of Securities)
Adam Simpson
Chief Executive Officer
Icosavax, Inc.
1930
Boren Avenue, Suite 1000
Seattle, Washington 98101
(206) 737-0085
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications
on Behalf of the Person Filing Statement)
With copies to:
|
|
|
| Cheston J. Larson
Matthew T. Bush
Latham & Watkins LLP
12670 High Bluff Drive
San Diego, CA 92130 (858)
523-5400 |
|
Elizabeth Bekiroğlu
General Counsel Icosavax,
Inc. 1930 Boren Avenue, Suite 1000
Seattle, Washington 98101
(206) 737-0085 |
| ☒ |
Check the box if the filing relates solely to preliminary communications made before the commencement of a
tender offer. |
The information set forth under Items 1.01, 8.01 and 9.01 of the Current Report on Form 8-K filed by Icosavax, Inc. on December 12, 2023 (including all exhibits attached thereto and incorporated therein by reference) is incorporated herein by reference.
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Icosavax (NASDAQ:ICVX)
Historical Stock Chart
From Jul 2023 to Jul 2024
